NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects

References

• Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 20202020/09/01/;37:101755.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020 Mar;38(1):1–9.
   PubMed Web of Science ®Google Scholar
• Attia YA, El-Saadony MT, Swelum AA, et al. COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review. Environ Sci Pollut Res. 2021;28(18):22241–22264. . 2021/ 03/18
   Web of Science ®Google Scholar
• *Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591(7848):92–98. . 2020/12/11
   Web of Science ®Google Scholar
• Karaderi T, Bareke H, Kunter I, et al. Host Genetics at the Intersection of Autoimmunity and COVID-19: a Potential Key for Heterogeneous COVID-19 Severity [Perspective]. Front Immunol. 2020 December;22(11):3314.
   Google Scholar
• *Schreiber G. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Front Immunol. 2020;11: 595739-595739.
   Web of Science ®Google Scholar
• King C, Sprent J. Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. Trends Immunol. 2021;42(4):312–322. . 2021/02/12/
   PubMed Web of Science ®Google Scholar
• Wei Lai, Ming Siqi, Zou Bin, et al. Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes during Q6 Covid-19 Infection. SSRN (Preprint). 2020;https://doi.org/10.2139/ssrn.3564998
   Google Scholar
• Haji Abdolvahab M, Moradi-kalbolandi S, Zarei M, et al. Potential role of interferons in treating COVID-19 patients. Int Immunopharmacol. 2021;90:107171. . 2021/01/01/
   PubMed Web of Science ®Google Scholar
• *Hirano T. Interleukin HT. 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):717–730.
   PubMed Web of Science ®Google Scholar
• Hong SK, Kim HJ, Song CS, et al. Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice. Int Immunopharmacol. 2012;13(1):23–27. . 2012/05/01/
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Devogelaer J-P, Damme JV, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheumatism. 1988;31(6):784–788. . 1988/06/01
   PubMedGoogle Scholar
• *Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021; 33(3): 127–148
   PubMed Web of Science ®Google Scholar
• Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40(1):37. . 2020/10/01
   PubMed Web of Science ®Google Scholar
• Meidaninikjeh S, Sabouni N, Marzouni HZ, et al. Monocytes and macrophages in COVID-19: friends and foes. Life Sci. 2021;269:119010. . 2021/03/15/
   PubMed Web of Science ®Google Scholar
• Tsang HF, Chan LWC, Cho WCS, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther 2020 1–12 https://doi.org/10.1080/14787210.2021.1863146
   Google Scholar
• **Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacol Res. 2020 Jul;157:104874.
   PubMed Web of Science ®Google Scholar
• Cadegiani FA, Goren A, Wambier CG, et al. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients. medRxiv. 2020;2020. DOI:https://doi.org/10.1101/2020.10.31.20223883.
   Google Scholar
• *Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J 2020 2003725 https://doi.org/10.1183/13993003.03725-2020
   Google Scholar
• Mendieta Zerón H, Meneses Calderón J, Paniagua Coria L, et al. Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel. World Acad Sci J. 2021;3(3):23. 2021/03/01.
   Google Scholar
• Rossignol J-F. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227–230. . 2016/05/01/
   PubMed Web of Science ®Google Scholar
• Di Santo N, Ehrisman J. Research Perspective: potential Role of Nitazoxanide in Ovarian Cancer Treatment. Old Drug, New Purpose? Cancers (Basel). 2013;5(4):3.
   Google Scholar
• Khan A, Slifer T, Araujo F, et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999;11(2):121–132. . 1999/02/01/
   PubMed Web of Science ®Google Scholar
• Patel A, Joseph J, Periasamy H, et al. Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis. Antimicrob Agents Chemother. 2018;62(9):e00752–18. .
   PubMed Web of Science ®Google Scholar
• *Zimmermann P, Ziesenitz VC, Curtis N, et al. The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms [Systematic Review]. Front Immunol. 2018-March-13. 2018;9(302). https://doi.org/10.3389/fimmu.2018.00302
   Google Scholar
• Hodge S, Hodge G, Brozyna S, et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28(3):486–495. . 2006/09//
   PubMed Web of Science ®Google Scholar
• *Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020;88:106903. . 2020/11/01/
   PubMed Web of Science ®Google Scholar
• Shalhoub S. Interferon beta-1b for COVID-19. Lancet. 2020;395(10238):1670–1671. (London, England). .
   PubMed Web of Science ®Google Scholar
• *Mary A, Hénaut L, Macq PY, et al. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience [Hypothesis and Theory]. Front Pharmacol. 2020-November-30. 2020;11(1885). https://doi.org/10.3389/fphar.2020.592543
   Google Scholar
• Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86: 106749-106749.
   Web of Science ®Google Scholar
• Jorgensen SCJ, Tse CLY, Burry L, et al. Baricitinib: a Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Pharmacother J Human Pharmacol Drug Ther. 2020;40(8):843–856. . 2020/08/01
   Google Scholar
• **Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982. . 2021/01/01/
   PubMed Web of Science ®Google Scholar
• *Kelleni MT. ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacology. 2020 Dec;28(6):1477–1480.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Masala IF, Sarzi-Puttini PA. Review of Chronic Musculoskeletal Pain: central and Peripheral Effects of Diclofenac. Pain Ther. 2018;7(2):163–177. . 2018/12/01
   PubMed Web of Science ®Google Scholar
• Housby JN, Cahill CM, Chu B, et al. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS INHIBIT THE EXPRESSION OF CYTOKINES AND INDUCE HSP70 IN HUMAN MONOCYTES. Cytokine. 1999 1999/05/01/;11(5):347–358. .
   PubMed Web of Science ®Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641. . 2021/01/11
   PubMed Web of Science ®Google Scholar
• Singh P, Rastogi S, SSSBansal M, et al. A prospective study to assess the levels of interleukin-6 following administration of diclofenac, ketorolac and tramadol after surgical removal of lower third molars. J Maxillofac Oral Surg. 2015;14(2):219–225. .
   PubMedGoogle Scholar
• Mahdy AM, Galley HF, Abdel‐Wahed MA, et al. Differential modulation of interleukin‐6 and interleukin‐10 by diclofenac in patients undergoing major surgery. Br J Anaesth. 2002;88(6):797–802. . 2002/06/01/
   PubMed Web of Science ®Google Scholar
• Berg J, Fellier H, Christoph T, et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflammation Res. 1999;48(7):369–379. .
   PubMed Web of Science ®Google Scholar
• Gallelli L, Galasso O, Falcone D, et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. Osteoarthritis Cartilage. 2013 Sep;21(9):1400–1408.
   PubMed Web of Science ®Google Scholar
• Smith CE, Soti S, Jones TA, et al. Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors. Cell Chem Biol. 2017;24(3):281–292. . 1999/07/01
   PubMed Web of Science ®Google Scholar
• Kelleni M. NSAIDs Immunomodulation in COVID-19 Might Inhibit SARS CoV-2 ORF Proteins Induced Caspase Activation, Necroptosis and Endoplasmic Reticulum Stress. Authorea. 2021. Preprint. DOI:https://doi.org/10.22541/au.162126663.38675715/v2
   Google Scholar
• *Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med. 2021;3(4):919–923. . 2021/04/01
   PubMedGoogle Scholar
• Kaneko N, Kuo -H-H, Boucau J, et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell. 2020;183(1):143–157.e13. . 2020/10/01/
   PubMed Web of Science ®Google Scholar
• Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother. 2016;12(9):2391–2402.
   PubMed Web of Science ®Google Scholar
• Chow JH, Khanna AK, Kethireddy S, et al. Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. Anesthesia Analg. 2021;132(4):4. .
   Web of Science ®Google Scholar
• *Kelleni M. Potential Crucial Role of COX-1 and/or COX-2 Inhibition, NSAIDs or Aspirin Triggered Lipoxins and Resolvins in Amelioration of COVID-19 Mortality. Authorea. 2021. Preprint. DOI:https://doi.org/10.22541/au.162126683.31375600/v1
   Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–350.
   PubMed Web of Science ®Google Scholar
• Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2020;79(2):276–284. .
   PubMed Web of Science ®Google Scholar
• Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Pediatr Anesthesia. 2008;18(10):915–921. . 2008/10/01
   PubMed Web of Science ®Google Scholar
• Kelleni M. Breakthrough: ibuprofen/nitazoxanide/azithromycin: a battle changer personalized COVID-19 telemedicine five days protocol. Authorea . 2020 June 22. (Preprint). DOI:https://doi.org/10.22541/au.159285564.49698842
   Google Scholar
• **Kelleni M. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: a Prospective Observational Study and Case-Series. Authorea. 2021 May:14. (Preprint). Doi: https://doi.org/10.22541/au.162126601.15715282/v2.
   Google Scholar